4.7 Review

Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment

期刊

PHARMACOLOGICAL RESEARCH
卷 174, 期 -, 页码 -

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2021.105938

关键词

THC; Cannabidiol; Adolescence; Schizophrenia; Animal model; Neurodevelopment

资金

  1. SoMoPro II Programme [3SGA5789]
  2. project Pharmacological research in the field of pharmacokinetics, neuropsychopharmacology, and oncology at Masaryk University, Brno, Czech Republic [MUNI/A/1249/2020]
  3. Piano triennale per la Ricerca-Linea Intervento 2
  4. Bando CHANCE-Linea Intervento 1
  5. University of Catania, Italy

向作者/读者索取更多资源

The recent trend of liberalization in Cannabis use has raised concerns about its impact on vulnerable populations, such as adolescents. Increasing daily use of Cannabis among adolescents, along with a decline in perceived harms, may lead to compromised social and cognitive functioning in adulthood. Cannabis exerts its effects by altering signaling within the endocannabinoid system, potentially impacting neurodevelopment and leading to adult neurodevelopmental deficits.
The recent shift in socio-political debates and growing liberalization of Cannabis use across the globe has raised concern regarding its impact on vulnerable populations such as adolescents. Concurrent with declining perception of Cannabis harms, more adolescents are using it daily in several countries and consuming marijuana strains with high content of psychotropic delta (9)-tetrahydrocannabinol (THC). These dual, related trends seem to facilitate the development of compromised social and cognitive performance at adulthood, which are described in preclinical and human studies. Cannabis exerts its effects via altering signalling within the endocannabinoid system (ECS), which modulates the stress circuitry during the neurodevelopment. In this context early interventions appear to circumvent the emergence of adult neurodevelopmental deficits. Accordingly, Cannabis sativa second-most abundant compound, cannabidiol (CBD), emerges as a potential therapeutic agent to treat neuropsychiatric disorders. We first focus on human and preclinical studies on the long-term effects induced by adolescent THC exposure as a critical window of enhanced neurophysiological vulnerability, which could be involved in the pathophysiology of schizophrenia and related primary psychotic disorders. Then, we focus on adolescence as a window of opportunity for early pharmacological treatment, as novel risk reduction strategy for neurodevelopmental disorders. Thus, we review current preclinical and clinical evidence regarding the efficacy of CBD in terms of positive, negative and cognitive symptoms treatment, safety profile, and molecular targets.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据